An in-depth analysis of original antigenic sin in dengue virus infection

Journal of Virology

Volumn 85, Issue 1, 2011, Pages 410-421

  Midgley, Claire M ^a   Bajwa Joseph, Martha ^a   Vasanawathana, Sirijitt ^b   Limpitikul, Wannee ^c   Wills, Bridget ^d   Flanagan, Aleksandra ^e   Waiyaiya, Emily ^a   Tran, Hai Bac ^a   Cowper, Alison E ^a   Chotiyarnwon, Pojchong ^a,g   Grimes, Jonathan M ^e   Yoksan, Sutee ^f   Malasit, Prida ^g,h   Simmons, Cameron P ^d   Mongkolsapaya, Juthathip ^a,g   Screaton, Gavin R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KHON KAEN HOSPITAL   (Thailand)

^c Songkhla Hospital   (Thailand)

^d OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MAHIDOL UNIVERSITY   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; DENGUE VACCINE; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADOLESCENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CHILD; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIMARY INFECTION; PRIORITY JOURNAL; SCHOOL CHILD; SECONDARY INFECTION; VACCINATION; VIRUS IMMUNITY;

DENGUE VIRUS; DENGUE VIRUS GROUP;

EID: 78650069522     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01826-10     Document Type: Article

References (71)

1. Alvarez, M., R. Rodriguez-Roche, L. Bernardo, S. Vazquez, L. Morier, D. Gonzalez, O. Castro, G. Kouri, S. B. Halstead, and M. G. Guzman. 2006. Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am. J. Trop. Med. Hyg. 75:1113-1117.
2. Balsitis, S. J., K. L. Williams, R. Lachica, D. Flores, J. L. Kyle, E. Mehlhop, S. Johnson, M. S. Diamond, P. R. Beatty, and E. Harris. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6:e1000790.
3. Bernardo, L., L. Hermida, J. Martin, M. Alvarez, I. Prado, C. Lopez, R. Martinez, R. Rodriguez-Roche, A. Zulueta, L. Lazo, D. Rosario, G. Guillen, and M. G. Guzman. 2008. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch. Virol. 153:849-854.
4. Blok, J. 1985. Genetic relationships of the dengue virus serotypes. J. Gen. Virol. 66:1323-1325.
5. Brien, J. D., S. K. Austin, S. Sukupolvi-Petty, K. M. O'Brien, S. Johnson, D. H. Fremont, and M. S. Diamond. 2010. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84:10630-10643.
6. Champion, A. B., K. L. Soderberg, and A. C. Wilson. 1975. Immunological comparison of azurins of known amino acid sequence. Dependence of crossreactivity upon sequence resemblance. J. Mol. Evol. 5:291-305.
7. Chin, J. F., J. J. Chu, and M. L. Ng. 2007. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 9:1-6.
8. Crill, W. D., H. R. Hughes, M. J. Delorey, and G. J. Chang. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991.
9. Crill, W. D., and J. T. Roehrig. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773.
10. Davenport, F. M., A. V. Hennessy, and T. Francis, Jr. 1953. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J. Exp. Med. 98:641-656.
11. East, I. J., P. E. Todd, and S. J. Leach. 1980. Original antigenic sin: experiments with a defined antigen. Mol. Immunol. 17:1539-1544.
12. Endy, T. P., A. Nisalak, S. Chunsuttitwat, D. W. Vaughn, S. Green, F. A. Ennis, A. L. Rothman, and D. H. Libraty. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189:990-1000.
13. Fazekas de St. Groth, S., and R. G. Webster. 1966. Disquisitions of Original Antigenic Sin. I. Evidence in man. J. Exp. Med. 124:331-345.
14. Fazekas de St. Groth, S., and R. G. Webster. 1966. Disquisitions on Original Antigenic Sin. II. Proof in lower creatures. J. Exp. Med. 124:347-361.
15. Francis, T., Jr. 1953. Influenza: the new acquayantance. Ann. Intern. Med. 39:203-221.
16. Goncalvez, A. P., R. E. Engle, M. St. Claire, R. H. Purcell, and C. J. Lai. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U. S. A. 104:9422-9427.
17. Green, S., and A. Rothman. 2006. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19:429-436.
18. Gromowski, G. D., and A. D. Barrett. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360.
19. Gromowski, G. D., N. D. Barrett, and A. D. Barrett. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837.
20. Gubler, D. J. 2002. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 33:330-342.
21. Gulati, U., K. Kumari, W. Wu, W. A. Keitel, and G. M. Air. 2005. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 23:1414-1425.
22. Halstead, S. B. 1979. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140:527-533.
23. Halstead, S. B., S. Nimmannitya, and S. N. Cohen. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42:311-328.
24. Halstead, S. B., and E. J. O'Rourke. 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265:739-741.
25. Halstead, S. B., and E. J. O'Rourke. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146:201-217.
26. Halstead, S. B., S. Rojanasuphot, and N. Sangkawibha. 1983. Original antigenic sin in dengue. Am. J. Trop. Med. Hyg. 32:154-156.
27. Hiramatsu, K., M. Tadano, R. Men, and C. J. Lai. 1996. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 224:437-445.
28. Huerta, V., G. Chinea, N. Fleitas, M. Sarria, J. Sanchez, P. Toledo, and G. Padron. 2008. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res. 137:225-234.
29. Hung, J. J., M. T. Hsieh, M. J. Young, C. L. Kao, C. C. King, and W. Chang. 2004. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J. Virol. 78:378-388.
30. Izquierdo, A., L. Bernardo, J. Martin, E. Santana, L. Hermida, G. Guillen, and M. G. Guzman. 2008. Serotype specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res. 138:135-138.
31. Jirakanjanakit, N., T. Sanohsomneing, S. Yoksan, and N. Bhamarapravati. 1997. The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue. Trans. R. Soc. Trop. Med. Hyg. 91:614-617.
32. Kaufman, B. M., P. L. Summers, D. R. Dubois, and K. H. Eckels. 1987. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:427-434.
33. Kaufmann, B., G. E. Nybakken, P. R. Chipman, W. Zhang, M. S. Diamond, D. H. Fremont, R. J. Kuhn, and M. G. Rossmann. 2006. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 103:12400-12404.
34. Kim, J. H., I. Skountzou, R. Compans, and J. Jacob. 2009. Original antigenic sin responses to influenza viruses. J. Immunol. 183:3294-3301.
35. Kliks, S. C., S. Nimmanitya, A. Nisalak, and D. S. Burke. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-419.
36. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
37. Konishi, E., S. Kosugi, and J. Imoto. 2006. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24:2200-2207. (Pubitemid 43255164)
38. Kuhn, R. J., W. Zhang, M. G. Rossmann, S. V. Pletnev, J. Corver, E. Lenches, C. T. Jones, S. Mukhopadhyay, P. R. Chipman, E. G. Strauss, T. S. Baker, and J. H. Strauss. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
39. Kuno, G., D. J. Gubler, and A. Oliver. 1993. Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections. Trans. R. Soc. Trop. Med. Hyg. 87:103-105.
40. Lai, C. Y., W. Y. Tsai, S. R. Lin, C. L. Kao, H. P. Hu, C. C. King, H. C. Wu, G. J. Chang, and W. K. Wang. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly crossreactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 82:6631-6643.
41. Libraty, D. H., L. P. Acosta, V. Tallo, E. Segubre-Mercado, A. Bautista, J. A. Potts, R. G. Jarman, I. K. Yoon, R. V. Gibbons, J. D. Brion, and R. Z. Capeding. 2009. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6:e1000171.
42. Lin, B., C. R. Parrish, J. M. Murray, and P. J. Wright. 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202:885-890.
43. Lok, S. M., V. Kostyuchenko, G. E. Nybakken, H. A. Holdaway, A. J. Battisti, S. Sukupolvi-Petty, D. Sedlak, D. H. Fremont, P. R. Chipman, J. T. Roehrig, M. S. Diamond, R. J. Kuhn, and M. G. Rossmann. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317.
44. Ludolfs, D., S. Schilling, J. Altenschmidt, and H. Schmitz. 2002. Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens. J. Clin. Microbiol. 40:4317-4320.
45. Matsui, K., G. D. Gromowski, L. Li, and A. D. Barrett. 2010. Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. J. Gen. Virol. 91:2249-2253.
46. Matsui, K., G. D. Gromowski, L. Li, A. J. Schuh, J. C. Lee, and A. D. Barrett. 2009. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384:16-20.
47. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100:6986-6991.
48. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-1231.
49. Mongkolsapaya, J., W. Dejnirattisai, X. N. Xu, S. Vasanawathana, N. Tangthawornchaikul, A. Chairunsri, S. Sawasdivorn, T. Duangchinda, T. Dong, S. Rowland-Jones, P. T. Yenchitsomanus, A. McMichael, P. Malasit, and G. Screaton. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921-927.
50. Oliphant, T., M. Engle, G. E. Nybakken, C. Doane, S. Johnson, L. Huang, S. Gorlatov, E. Mehlhop, A. Marri, K. M. Chung, G. D. Ebel, L. D. Kramer, D. H. Fremont, and M. S. Diamond. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
51. Powers, D. C., and R. B. Belshe. 1994. Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin." J. Infect. Dis. 169:1125-1129.
52. Rajamanonmani, R., C. Nkenfou, P. Clancy, Y. H. Yau, S. G. Shochat, S. Sukupolvi-Petty, W. Schul, M. S. Diamond, S. G. Vasudevan, and J. Lescar. 2009. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J. Gen. Virol. 90:799-809.
53. Roehrig, J. T., R. A. Bolin, and R. G. Kelly. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317-328.
54. Sabin, A. B. 1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30-50.
55. Shrestha, B., J. D. Brien, S. Sukupolvi-Petty, S. K. Austin, M. A. Edeling, T. Kim, K. M. O'Brien, C. A. Nelson, S. Johnson, D. H. Fremont, and M. S. Diamond. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6:e1000823.
56. Simmons, C. P., T. N. Chau, T. T. Thuy, N. M. Tuan, D. M. Hoang, N. T. Thien, L. B. Lien, N. T. Quy, N. T. Hieu, T. T. Hien, C. McElnea, P. Young, S. Whitehead, N. T. Hung, and J. Farrar. 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196:416-424.
57. Simmons, M., G. S. Murphy, and C. G. Hayes. 2001. Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 65:159-161.
58. Simmons, M., W. M. Nelson, S. J. Wu, and C. G. Hayes. 1998. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 58:655-662.
59. Srivastava, A. K., J. R. Putnak, R. L. Warren, and C. H. Hoke, Jr. 1995. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13:1251-1258.
60. Sukupolvi-Petty, S., S. K. Austin, M. Engle, J. D. Brien, K. A. Dowd, K. L. Williams, S. Johnson, R. Rico-Hesse, E. Harris, T. C. Pierson, D. H. Fremont, and M. S. Diamond. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84:9227-9239.
61. Sukupolvi-Petty, S., S. K. Austin, W. E. Purtha, T. Oliphant, G. E. Nybakken, J. J. Schlesinger, J. T. Roehrig, G. D. Gromowski, A. D. Barrett, D. H. Fremont, and M. S. Diamond. 2007. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826.
62. Thullier, P., C. Demangel, H. Bedouelle, F. Megret, A. Jouan, V. Deubel, J. C. Mazie, and P. Lafaye. 2001. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J. Gen. Virol. 82:1885-1892.
63. Vaughn, D. W., S. Green, S. Kalayanarooj, B. L. Innis, S. Nimmannitya, S. Suntayakorn, T. P. Endy, B. Raengsakulrach, A. L. Rothman, F. A. Ennis, and A. Nisalak. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
64. Volk, D. E., Y. C. Lee, X. Li, V. Thiviyanathan, G. D. Gromowski, L. Li, A. R. Lamb, D. W. Beasley, A. D. Barrett, and D. G. Gorenstein. 2007. Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364:147-154.
65. Wahala, W. M., E. F. Donaldson, R. de Alwis, M. A. Accavitti-Loper, R. S. Baric, and A. M. de Silva. 2010. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 6:e1000821.
66. Wahala, W. M., A. A. Kraus, L. B. Haymore, M. A. Accavitti-Loper, and A. M. de Silva. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-113.
67. Webster, D. P., J. Farrar, and S. Rowland-Jones. 2009. Progress towards a dengue vaccine. Lancet Infect. Dis. 9:678-687.
68. Webster, R. G. 1966. Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. J. Immunol. 97:177-183.
69. Whitehead, S. S., J. E. Blaney, A. P. Durbin, and B. R. Murphy. 2007. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5:518-528.
70. Wrammert, J., K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N. Y. Zheng, I. Mays, L. Garman, C. Helms, J. James, G. M. Air, J. D. Capra, R. Ahmed, and P. C. Wilson. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671.
71. Yenchitsomanus, P. T., P. Sricharoen, I. Jaruthasana, S. N. Pattanakitsakul, S. Nitayaphan, J. Mongkolsapaya, and P. Malasit. 1996. Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). Southeast Asian J. Trop. Med. Public Health 27:228-236.